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Introduction
The class of N,N-dialkylated tryptamines has been a constant element of interest within the context of new psychoactive substances (NPS) (Meatherall and Sharma, 2003; Smolinske et al., 2005; Tanaka et al., 2006; Vorce and Sklerov, 2004; Wilson et al., 2005) . Another newer tryptamine, 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT), was associated with a fatal poisoning (Elliott and Evans, 2014) .
In contrast to medicinal products with marketing authorization (http://medicine.iupui.edu/clinpharm/ddis/main-table/), drugs of abuse (DOA) and most NPS, are marketed and consumed without availability of information regarding their pharmacological and toxicological properties (Brandt et al., 2014) . One important part of safety testing is the evaluation of cytochrome P450 (CYP) inhibition in order to assess the potential for interactions when more than one drug (of abuse) is taken. Inhibition can lead to prolonged plasma elimination half-life and increased bioavailability, which can lead to increased risks of developing adverse reactions. They can cause increased number and/or duration of hospitalization (Palleria et al., 2013) . A systematic screening of methylenedioxy-derived designer drugs showed that these drugs are inhibitors of the main CYP isoenzymes, some with IC50 values in the range of clinically relevant inhibitors (Dinger et al., 2014c) .
The present study aimed to evaluate TDNPS for their inhibition potential towards relevant CYP isozymes. For this purpose, a two cocktail approach (Dinger et al., 2014a; Dinger et al., 2014b) was used to determine the inhibitor concentrations which reduced the enzyme activity by 50% (IC50 value). In addition, the in vitro inhibition potential against CYP1A2 of 5-MeO-DALT was confirmed in vivo using rats and caffeine as test substrate.
Materials and methods

Chemicals and reagents
Alpha-naphthoflavone, amodiaquine 2HCl, caffeine solution 1 mg/mL, coumarin, , and all other chemicals from VWR (Darmstadt, Germany). All non-scheduled tryptamines were prepared following procedures published previously (Brandt et al., 2012; Young, 1958 Indicator silica gel pearls KC were obtained from NeoLab Migge (Heidelberg, Germany).
LC-HR-MS/MS apparatus for in vitro cocktail incubations
All analytical features associated with instrumentation have been described in detail elsewhere (Dinger et al., 2014a) . Briefly, a Thermo Fisher Scientific (TF, Dreieich, Germany)
Aria Transcend TLX-I HTLC, together with a TF Accela 1250 pump, a TF HTC PAL autosampler, and a valve interface module were used with built-in switching valves, all controlled by the TF Aria software version 1.6.3. It was coupled to a TF Q-Exactive equipped with a heated electrospray ionization source (HESI-II). The gradient elution was performed on a TF Accucore RP-MS (150 x 2.1 mm, 2.6 µm) column using water containing 0.02% (v/v) formic acid pH 3.1 (eluent A) and acetonitrile containing 0.1% (v/v) formic acid (eluent B) and a flow rate of 600 µL/min. The injection volume for all samples was 10 µL.
The MS conditions were as follows: HESI-II, positive and/or negative mode; sheath gas, nitrogen at a flow rate of 60 arbitrary units (AU); auxiliary gas, nitrogen at a flow rate of 20 AU; vaporizer temperature, 350 °C; spray voltage, 3.00 kV positive and 4.00 kV negative; ion transfer capillary temperature, 380 °C; and S-lens RF level, 50.0.
A targeted single ion monitoring experiment with mass spectrometric multiplexing (msx) and inclusion list was performed using the protonated or deprotonated ions of the metabolites.
For the detection of O-deethyl phenacetin and N-deethyl amodiaquine, fragment ions obtained from in-source collision induced dissociation with 25 eV were used.
The scan parameters were as follows: microscan, 1; resolution, 17,500; AGC target, 1e6; maximum injection time, 250 ms; msx count, 5; isolation window, 1 m/z; scan range, m/z 100-400. The scan parameters were the same for positive and negative mode.
TF Xcalibur 2.2 software was used for data handling. The settings for automated peak integration were as follows: peak detection algorithm, ICIS; smoothing, 7; area noise factor, 5;
and peak noise factor, 10.
Preparation of stock solutions and spiking solutions for in vitro inhibition experiments
The specific substrates, their metabolites, and model inhibitors were used and prepared in accordance to Dinger et al. (Dinger et al., 2014b) . All stock solutions (10 mM) for the test inhibitors (tryptamines) were prepared in water/methanol 9/1 (v/v) with the exception of 4,5-
. These stock solutions were serially diluted with phosphate buffer for the incubations.
Conditions for the cocktail incubations
The conditions were already described elsewhere (Dinger et al., 2014b) . Briefly, microsomal incubations were performed at 37°C for 15 min with 0.2 mg/mL pHLM and the test substrates, split in two cocktails. Incubation time and protein content were in the linear range of product formation for all incubated enzymes and corresponding substrates. µM). The incubation mixtures were centrifuged for 5 min at 14,000 g, 40 µL of both supernatants (cocktail A and B) were pooled, transferred to an autosampler vial, and 10 µL were injected onto the LC-HR-MS/MS apparatus for analysis under the conditions described above.
Prescreening and determination of IC50 values 2.5.1. Prescreening
According to Dinger et al. (Dinger et al., 2014c) , the general inhibition potential of the TDNPS was tested using the cocktails incubated with 100 µM of each TDNPS (structures given in Fig. 1 ) in triplicates. In addition to these samples, control samples without inhibitor, positive control samples with model inhibitors (20 µM), and interfering samples were also prepared in triplicates. For the interfering samples, control samples without inhibitor were incubated and the reaction was terminated with ice-cold acetonitrile containing the IS and the tested TDNPS. For sample evaluation, the metabolite formation in the incubation sample was compared to the formation in the control sample. Every inhibition sample was compared with every control sample (n = 3 each).
Determination of IC50 values
According to Dinger et al. (Dinger et al., 2014c) , the IC50 values were determined in duplicate for TDNPS, showing more than 50% inhibition of the activity of one or more isoenzymes. The TDNPS were used at ten different concentrations (0.01, 0.05, 0.1, 1, 10, 50, 100, 200, 400, 800 µM). Control, positive control, and interfering samples were also prepared as described above. The IC50 values were calculated by plotting the metabolite formation (relative to the control sample) over the logarithm of the TDNPS (inhibitor) concentration using GraphPad Prism 5.00 (GraphPad Software, San Diego, CA, USA). Relative metabolite formation was calculated by division of every inhibition sample with every control sample (n = 2 each). Statistic evaluation of the IC50 values were also performed using GraphPad Prism 5.00.
In vivo CYP1A2 inhibition testing for 5-MeO-DALT
LC-MS/MS apparatus
All samples were analyzed using a TF TSQ Quantum Access mass spectrometer coupled to a TF Accela UHPLC system consisting of a degasser, a quaternary pump, and an autosampler. Gradient elution was performed on a TF Accucore RP-MS column (150×2.1 mm, 2.6 μm). The mobile phase consisted of water plus 0.01% formic acid (eluent A) and methanol plus 0.01% formic acid (eluent B). The flow rate was set to 700 μL/min, and the gradient was programmed as follows: 0-1.5 min to 85% A, 1.5-2.5 min to 70% A, 2.5-3.1 min hold, 3.1-4.5 min to 60% A, 4.5-6.5 min to 5% A, 6.5-7.5 min hold, 7.5-7.6 back to 85% A and hold till 10 min.
The MS conditions were as follows: atmospheric pressure chemical ionization (APCI), positive mode, sheath gas, nitrogen at a flow rate of 40 arbitrary units; auxiliary gas, nitrogen at flow rate of ten arbitrary units; collision gas, argon; vaporizer temperature, 300 °C; discharge current, 4.0 μA; ion transfer capillary temperature, 250 °C; and capillary offset, 35 V.
The mass spectrometer was operated in the timed multiple-reaction monitoring (MRM) mode with the following settings: collision pressure, 1.5 mTorr; isolation width Q1, 0.7 units;
and scan time, 1 s. Transitions and their particular settings, collision energy, and tube lens were optimized for each analyte. All MRM transitions, collision energies, tube lens settings, and retention times used for the given analytes are summarized in Table 1 . For data evaluation, TF Xcalibur 2.1.0 were used to obtain peak areas. The settings were as follows: peak detection algorithm ICIS; smoothing, 5; and area-to-noise factor, 5, peak-to-noise factor 10. GraphPad Prism 5.00 was used for statistical analysis.
Preparation of stock solutions, calibration standards, and control samples for validation of the LC-MS/MS method
Two different methanolic stock solutions (1.0 mg/mL) of caffeine were used. For 8chlorotheophylline, fluvoxamine, 5-MeO-DALT, theobromine, and theophylline, methanolic solutions (1.0 mg/mL) were prepared and for paraxanthine a standard methanolic solution (1.0 mg/mL) was used.
Working solutions (0.01 and 0.1 mg/mL) of analytes were prepared in methanol by dilution from each stock solution. The spiking solutions for calibration standards and quality control (QC) samples were prepared by adding the appropriate amount of the corresponding stock or working solution to volumetric flasks to obtain the corresponding plasma or spot concentration. Calibration standards were prepared freshly every day spotting 10 μL of the corresponding spiking solution to a 30 µL blank dried blood spots (DBS). QC samples were prepared at two different concentrations (LOW and HIGH) in the same way than the calibration standards and additionally by spiking fresh whole blood with the solution, ten times higher than the recommended concentration, before spotting.
Method validation for caffeine quantification
The method was validated as recommended for single case analysis, including selectivity, recovery, matrix effects, process efficiency, linearity, accuracy and precision, and limit of quantification (Peters et al., 2007) . Additionally, it was evaluated whether blank DBS could be used to prepare calibrators and QC samples. Therefore, blank rat blood was spiked at low and high concentration before spotting and blank DBS were spiked with the corresponding concentrations (n=6, each). The peak areas of both sample sets were compared using a twotailed unpaired t-test using Graphpad prism. Selectivity was determined by analyzing six blank DBS in multiple reaction monitoring mode (MRM) to check for signals that might interfere with caffeine or the IS. In addition, two zero samples (blank spot including IS) were analyzed.
Matrix effects were determined according to Matuszewski et al. (Matuszewski et al., 1998) analyzing six samples for each sample set at low and high concentration. Sample set 1 consisted of neat standard solution, set 2 of extracted blank DBS spiked after extraction, and set 3 of the extracted spiked DBS. The calibration at six different concentrations (0.05, 1, 3, 5, 7, 10 mg/L) was performed in duplicate and analyzed as described above. The regression line was calculated using a first-order polynomial weighted (1/x 2 ) least-squares model. Six QC samples at low (0.1 mg/L) and high (9 mg/L) concentrations were analyzed and determined based on calibration curves. Accuracy was calculated in terms of bias as the percent deviation of the mean calculated concentration at each concentration from the corresponding theoretical concentration. Precision was calculated as the relative standard deviation (RSD). The lower limit of quantification (LLOQ) of the method was defined as the concentration of the QC low and was checked for the acceptance criterion of a signal-to-noise (S/N) ratio of >10.
Theobromine, theophylline, fluvoxamine and 5-MeO-DALT, and paraxanthine were qualitatively monitored to exclude interferences. (Wickremsinhe, 2015) . Blank blood samples for calibration standards were collected before drug administration and spotted directly. DBS were stored in exsiccator with silica gel pearls as drying agent at room temperature until analysis.
Extraction procedure for DBS
The DBS were extracted according to de Kesel et al. (De Kesel et al., 2014) . In contrast, the whole DBS was punched and divided in 4 parts. These parts were extracted with 280 µL of a mixture of methanol and water 80/20 (v:v) containing 0.01% of formic acid and 1 mg/L of 8chlorotheophylline as internal standard (IS) for 10 minutes on a rotary shaker. Afterwards, the samples were centrifuged for 10 min at 14680 rpm and 200 µL of the upper phase was transferred to a glass vial. The solvent was evaporated under a stream of nitrogen at 70°C and reconstituted in 100 µL of solvent A. Ten microliters of this extract were injected onto the LC-MS/MS system.
Determination of in vivo CYP1A2 inhibition by 5-MeO-DALT
The inhibition effects on the metabolism of caffeine were determined by calculating the kinetic constants area under the plasma concentration/time curve (AUC), Cmax, and tmax for all groups. The AUC was calculated using the trapezoidal rule. The Bateman equation (equation 1) was used for calculating cmax and tmax.
Results and discussion
Prescreening and determination of IC50 values
For all incubations, protein and time courses were tested for all isoenzyme/substrate reactions, and incubation conditions were chosen accordingly. The protein concentration of 0.2 mg/mL was sufficient for analyzing the specific substrate metabolites and were not expected to
show non-specific protein binding (Baranczewski et al., 2006) . In addition, the Food and Drug Microsomes were used instead of hepatocytes or liver tissues, because the enzyme concentrations were much higher in microsomes (Lu, 2014) . Thus, smaller sample amounts could be used reducing the risk of unspecific protein bindings. Suitable incubation conditions were monitored incubating positive control samples with a mixture of the model inhibitors (20 µM) of each isoenzyme (Dinger et al., 2014b) . Analytical interferences such as ion suppression or enhancement caused by co-eluting TDNPS were tested using incubated control samples (no inhibitor). The incubation was terminated with acetonitrile containing the internal standards and the corresponding TDNPS (Dinger et al., 2014a) . These samples were prepared to avoid false positive inhibition results in case of ion suppression or negative results in case of ion enhancement. This was necessary because only the specific metabolites were monitored by the analytical method and possibly co-eluting TDNPS were not detected. All control samples (without inhibitor) were compared to each incubation sample (n = 3 each for prescreening, n = 2 each for IC50 value determination).
As shown in Fig. 2 , DMT was the only compound without inhibition of any isoenzyme activities. All others showed inhibition on CYP2D6 resulting in less than 50% activity in the prescreening experiment. All tested members of the DALT family reduced the CYP1A2 activity to less than 20% activity. Analytical interferences could be excluded. All isoenzymes were inhibited by the specific inhibitors in the positive controls. These kind of prescreening experiments were performed to gain a general overview of the inhibition potential for the tested drugs. A tryptamine concentration of 100 µM was chosen because at that concentrations, no or only slight inhibition could be considered as clinically irrelevant. Clinically relevant inhibitors showed IC50 values of about 100 µM (Bertelsen et al., 2003; Brosen et al., 1993; Burt et al., 2010; Ewald and Maurer, 2008; Kobayashi et al., 1998; Niwa et al., 2005; Park et al., 2003; von Moltke et al., 1998; Wang et al., 2002; Xu and Desta, 2013) . Therefore, the IC50 values were only determined for TDNPS that showed inhibition of more than 50%. Performing such pre-experiments was helpful to save time and costs if isoenzymes of only one of both cocktails or no isoenzymes were inhibited. Thus, the IC50 values of DMT were not determined and for 2-Me-AMT, only cocktail A had to be incubated. For all other tested TDNPS, both cocktails were incubated because at least one isoenzyme each was inhibited during the prescreening.
As can be seen in Table 2, all tested TDNPS showed inhibition against at least one isoenzyme   of the nine tested with IC50 values comparable to corresponding known clinically relevant inhibitors. However, to assess the clinical relevance based on IC50 values of known drugs, the plasma levels of these drugs and the tested TDNPS have to be considered (given in Table 2) .
Plasma concentrations of the tested tryptamines are only published for AMT and 5-MeO-DiPT (0.9-7.5 µM, 0.14-1.7 mg/mL). Common dosage levels associated with a range of psychoactive tryptamines were described to vary considerably although ranges between 5-60 mg were not uncommon (Shulgin and Shulgin, 1997) . For most of the tested tryptamines, no data were available in the published literature but similar doses and therefore, similar plasma concentrations were considered acceptable (in the range of 0.5-9 µM). All tested AMTs, all DALTs, 5-MeO-2-Me-DMT, and 4-HO-DiPT showed inhibition against CYP1A2 activity. All
DALTs showed IC50 values against CYP1A2 activity below 1 µM, being in the same range as the strong inhibitor fluvoxamine (IC50 value of 0.2 µM). Compared to the probe inhibitor alpha-naphthoflavone, the values were up to 10 times higher. The assumed plasma levels were in the same range as those for fluvoxamine. Based on these data, clinical relevance of the CYP1A2 inhibition by DALTs could not be excluded. This inhibition could especially be relevant for co-administered drugs such as clozapine, which were exclusively metabolized by CYP1A2. Severe clozapine intoxications caused by CYP1A2 inhibition were known as problem under the treatment with clozapine (Heeringa et al., 1999; Pinninti and de, 1997; Van Strater and Bogers, 2012 ). Five of the tested AMT showed values below 50 µM and the other inhibitors showed higher IC50 values (105-336 µM). For the AMTs, clinical relevance could also not be excluded although the values were higher than for the DALTs. However, they were below the range of the IC50 value of amiodarone (IC50 value of 86 µM), a known CYP1A2 inhibitor, with plasma levels of the AMTs comparable with that of amiodarone. Comparing the structural properties and the IC50 values, it seemed that the N,N-diallyl group enhanced the inhibition potential in contrast to the alpha-methyl, dimethyl, or diisopropyl groups. However, the substituents in positions 2, 5, 6, or 7 enhanced the potential significantly compared to DALT itself, but no difference between these substituents could be observed. In contrast to that family, the different substituents of the AMTs influenced the inhibition potential. Methylation However, clinical relevance cannot be excluded as this tryptamine showed lower IC50 values than efavirenz. However, interaction could be relevant for polydrug users under substitution with methadone, which is metabolized by CYP2B6 to EDDP, resulting in increased methadone levels (Kharasch et al., 2015) . For the other TDNPS, comparably weak inhibition with values DALT was in the range of that of gemfibrozil (IC50 value of 91 µM), a known inhibitor (Niemi et al., 2003) . The described plasma level of trimethoprim was also comparable to that of the tryptamines, so a clinical relevance could not be excluded for 4,5-ED-DALT. In contrast, the plasma levels of gemfibrozil were described as much higher than that of the tryptamines, so , the values were hundred times higher (Dinger et al., 2014b) . The plasma levels of all TDNPS were lower than those of fluconazole and thus, clinical relevance of the inhibition of CYP2C9 activity by these TDNPS seemed to be improbable. CYP2C19 activity was inhibited by AMT, five members of the DALT family, and 4-HO-DiPT with values between 33 and 88 µM. These values were in the range of the IC50 value of 32 µM of chloramphenicol, a known inhibitor with clinical relevance (Hafner et al., 2008; Koup et al., 1978) and slightly above the probe inhibitor fluconazole (IC50 value of 17 µM). Concerning the plasma levels, the levels of fluconazole and chloramphenicol were much higher than those of the tryptamines (4.9-31 µM), so a clinical relevance of these inhibition potentials seemed also improbable. The other nine tryptamines showing CYP2C19 inhibition had values above 100 µM and these values could be seen to be not really clinically relevant. As already seen during the prescreening experiments, CYP2D6 was inhibited by all tested tryptamines with the exception of DMT. All determined IC50 values were below 100 µM. The DALTs showed the strongest inhibition with values below 5 µM with the exception of 5-MeO-DALT (13 µM) and were in the same range as those of the well-known clinically relevant inhibitors paroxetine and fluoxetine (IC50 values of 2.85 µM and Ki value of 8.2 µM). The IC50 values of 5-F-2-Me-DALT, 6-F-DALT, and 7-Me-DALT were even comparable with the value of the CYP2D6 probe inhibitor quinidine (0.1 µM). Three of the AMTs and one of the tested DiPTs also inhibited CYP2D6 activity in the same range as the known inhibitors. The plasma levels of all tested TDNPS were in comparable ranges as those of paroxetine and fluoxetine.
Therefore, the inhibition potential of these drugs might be of clinical relevance. The inhibition of this isoenzyme could be critical because a lot of therapeutic and abused drugs are metabolized by this isoenzyme (http://medicine.iupui.edu/clinpharm/ddis/clinical-table/). The therapeutic effect of prodrugs such as risperidone or tramadol could not be effective.
Antidepressive such as amitriptyline, clomipramine, venlafaxine or neuroleptics such as haloperidol are also metabolized by this isoenzyme. Inhibition of their metabolism could result in increased plasma levels and intoxication symptoms. Comparing the structural properties and the determined IC50 values, it seemed that the IC50 values increased from diallyl, over alphamethyl and dimethyl to diisopropyl-substituted tryptamines. This could be observed for all tested tryptamines. The second correlation was that the IC50 values decreased from drugs with methyl or fluoro substituents in position 5 to those with chloro substituents. In contrast, the substitution by methyl or fluoro group influenced the inhibition potential in the same range.
Substitution in position 6 and 7 by a fluoro or methyl group prefer the CYP2D6 inhibition by
DALTs in contrast to AMTs. CYP2E1 activity was reduced by 19 tryptamines with 5-Me-DALT, 5-MeO-DALT and 5-MeO-2-Me-DMT showing the highest potential with IC50 values of 11, 20, and 20 µM, respectively. Only these IC50 values were comparable with the values of the probe inhibitor clomethiazole (IC50 value of 10.9 µM). (Dinger et al., 2014b; Gebhardt et al., 1997) . The IC50 values and the plasma concentrations were in the same range, so a clinical relevance of the CYP2E1 inhibition could not be excluded for these three compounds.
However, the values of the other tryptamines were much higher but a clinical relevance could also not be excluded. Eighteen of the tested TDNPS showed also inhibition against CYP3A activity. All DALTs showed inhibition potentials (IC50 values 31-114 µM) in the range of the protease inhibitor saquinavir (IC50 value of 11.5 µM), the calcium channel blocker verapamil (IC50 value of 22 µM)., the probe inhibitor for CYP3A, and the time-dependent inhibitor clarithromycin (IC50 value of 116 µM). The clinical relevance of verapamil inhibition is wellknown. For example, Kandavar and Sander described a multi-organ failure caused by coadministration of the CYP3A substrate atorvastatin and the CYP3A inhibitor verapamil (Kandavar and Sander, 2010) . were in the same range as that of the tryptamines, clinically relevant interaction could not be excluded. In contrast, the therapeutic plasma levels of the antibiotic clarithromycin were much higher than for the tested TDNPS with the exception of poisoning cases. Because of these data, the inhibition potentials of these drugs against CYP3A activity could be assessed as weak.
Concerning the structural properties and the IC50 values of the DALT family, it seemed that introduction of substituents in 5 or 6 positions enhanced the inhibition potential. The values of DALT itself and the substituted analogues, with the exception of 5-Cl-DALT and 5-MeO-DALT, were significantly different. Substitution of both positions with methylenedioxy bridge showed the highest effect (Dinger et al., 2014c) .
3.3. In vivo inhibition potential of 5-MeO-DALT
Quantification of caffeine
For determination of the corresponding caffeine concentrations in rat blood by LC-MS/MS, DBS were prepared to save blood volume. Besides common validation parameters, the usage of blank DBS for preparing calibrators and QC samples was evaluated. Using a twotailed unpaired t-test, the peak areas of sample set 1 (whole blood spiked before spotting) and set 2 (blank DBS spiked after spotting) at low and high concentration were not significantly different (p<0.05). The method was selective for caffeine as well as for the IS and no interfering peaks could be detected in the MRM mode. Results for recovery, matrix effect, process efficiency, accuracy, and precision are summarized in Table 3 . The calibration curves were linear and the back-calculated calibrators were within the acceptance criteria. The LLOQ was consistent with the lowest calibrator and within the required acceptance criteria. The used blood volume for spotting was 30 µL. According to Wickremsinhe (Wickremsinhe, 2015) there was no difference between 10, 20 or 30 µL spot volume. Thus, 30 µL was used for more sensitive determination of caffeine. The whole spot was punched avoiding variations in spread area caused by different hematocrit values (Wickremsinhe, 2015) .
Determination of in vivo inhibition potential of 5-MeO-DALT
According to Kot and Daniel, CYP1A2 metabolized over 80% of caffeine in humans and rats and only the metabolite profile differed (Kot and Daniel, 2008 al., 2006) . To monitor also a rapidly reversible inhibition, the substrate and the inhibitor were given simultaneously because the mode of inhibition was not known for 5-MeO-DALT. As positive control, the known CYP1A2 inhibitor fluvoxamine was tested under the same conditions. Results are summarized in Table 4 . The control group (only caffeine administration) showed the lowest AUC of the plasma concentration time curve with 36 h*mg/L, in good correlation with described values (Latini et al., 1978) . For the positive control group, the AUC was about three times higher than for the control group, proving the study design. The AUC of test group was 307 h*mg/L. The control group showed the lowest Cmax value of 4.2 mg/L. For the other two groups, the value increased five times compared to the control group. Tmax was for all groups in the same range (1.9 -2.6 h). The tested kinetic parameters of caffeine increased for the positive and test group instead of the control group as expected according to the in vitro data. Hence, in vivo data seemed to confirm the in vitro data for 5-MeO-DALT. However, further studies with larger groups are needed to confirm this observation.
Conclusions
The presented study showed that with the exception of DMT all tested TDNPS showed more or less inhibition potential against the various CYP isoforms. Thus, these TDNPS could change the pharmacokinetics, namely the plasma levels and the corresponding effects of co-administered therapeutics or NPS. Prodrugs such as tramadol, tilidine, or risperidone, mainly metabolized by one or two isoenzyme, could lose their potency, if bioactivation was blocked (Mannheimer et al., 2008; Stamer et al., 2007; Wustrow et al., 2012) . Neuroleptics such as clozapine or haloperidol could accumulate in plasma and lead to toxic concentrations (Murray, 2006) . The inhibition of CYP2D6 and CYP3A4 could be important because many endogenous compounds and xenobiotics were metabolized by these two isoenzymes (http://medicine.iupui.edu/clinpharm/ddis/clinical-table/). However, it should be kept in mind that clinical cases or studies would be desirable to finally assess the risks associated with drug-drug interactions.
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Legends to the Figures
DALT-type
DALT 0.14-1.7 (Elliott and Evans, 2014; Tanaka et al., 2006; Wilson et al., 2005) 0.6-7.1 0.4 (± 0.1) 175 (± 105) 2.6 (± 2) 91(± 12) 90 (± 12) 5-F-DALT 0.14-1.7 (Elliott and Evans, 2014; Tanaka et al., 2006; Wilson et al., 2005) 0.5-6.6 0.9 (± 0.5) 64 (± 10) 109 (± 5.6) 200 (± 13) 4.8 (± 0.9) 390 (± 8.7) 75 (± 8.1) 5-F-2-Me-DALT 0.14-1.7 (Elliott and Evans, 2014; Tanaka et al., 2006; Wilson et al., 2005) 0.5-6.3 0.8 (± 0.3) 30 (± 1.4) 199 (± 3.3) 63 (± 2.2) 33 (± 1.8) 0.8 (± 0.1) 146 (± 74) 31 (± 3.1)
5-Cl-DALT
0.14-1.7 (Elliott and Evans, 2014; Tanaka et al., 2006; Wilson et al., 2005) 0.5-6.2 0.3 (± 0.009) 39 (± 12) 190 (± 52) 31 (± 0.8) 36 (± 11) 1.2 (± 0.3) 135 (± 76) 59 (± 23) 5-Br-DALT 0.14-1.7 (Elliott and Evans, 2014; Tanaka et al., 2006; Wilson et al., 2005) 0.4-5.3 0.8 (± 0.2) 52 (± 0.6) 176 (± 15) 23 (± 0.04) 52 (± 3.4) 2.5 (± 0.4) 122 (± 58) 60 (± 16) 5-Me-DALT 0.14-1.7 (Elliott and Evans, 2014; Tanaka et al., 2006; Wilson et al., 2005) 0.6-6.7 0.7 (± 0.5) 138 (± 14) 77 (± 13) 156 (± 3.4) 3.8 (± 0.7) 11 (± 12) 67 (± 9.8)
5-MeO-DALT
0.14-1.7 (Elliott and Evans, 2014; Tanaka et al., 2006; Wilson et al., 2005) 0.5-6.3 0.4 (± 0.1) 0.8 (± 0.9) 111 (± 128) 13 (± 11) 20 (± 14) 114 (± 36) 6-F-DALT 0.14-1.7 (Elliott and Evans, 2014; Tanaka et al., 2006; Wilson et al., 2005) 0.5-6.6 0.3 (± 0.02) 48 (± 16) 75 (± 84) 71 (± 8.4) 48 (± 14) 0.3 (± 0.05) 48 (± 55) 42 (± 14)
7-Me-DALT 0.14-1.7 (Elliott and Evans, 2014; Tanaka et al., 2006; Wilson et al., 2005) 0.6-6.7 0.1 (± 0.03) 135 (± 45) 159 (± 31) 261 (± 79) 0.2 (± 0.2) 238 (± 48) 84 (± 12) 5,6-MD-DALT (Dinger et al., 2014c) 0.14-1.7 (Elliott and Evans, 2014; Tanaka et al., 2006; Wilson et al., 2005) 0.5-6 0.3 (± 0.2) 26 (± 15) 58 (± 0.7) 58 (± 17) 0.4 (± 0.3) 15 (± 0.1) 4,5-ED-DALT 0.14-1.7 (Elliott and Evans, 2014; Tanaka et al., 2006; Wilson et al., 2005) 0.5-5.7 0.1 (± 0.01) 139 (± 121) 66 (± 28) 17 (± 20) 116 (± 9.2) 55 (± 26) 2.9 (± 0.8)
(± 20)
DMT-type DMT 0.14-1.7 (Elliott and Evans, 2014; Tanaka et al., 2006; Wilson et al., 2005) 0.7-9 5-MeO-2-Me-DMT 0.14-1.7 (Elliott and Evans, 2014; Tanaka et al., 2006; Wilson et al., 2005) 0.6-7.3 198 (± 107) 377 (± 80) 57 (± 1) 20 (± 6)
DiPT-type 4-HO-DiPT 0.14-1.7 (Wilson et al., 2005) ( Tanaka et al., 2006) 0.5-6.5 297 (± 3.3) 450 (± 175) 271 (± 78) 88 (± 23) 9.6 (± 2.4) 60 (± 6.2) 115 (± 2.2) 5-MeO-2-Me-DiPT 0.14-1.7 (Wilson et al., 2005 ) (Tanaka et al., 2006 
